Zentalis Pharmaceuticals entered into an underwriting agreement to sell 23,000,000 shares of common stock at $3.50 per share, with a 30-day option for the underwriters to purchase up to 3,450,000 additional shares. The company estimates net proceeds of approximately $75.1 million after deducting discounts and expenses. Closing is expected on August 17, 2026. Proceeds will fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostics, and general corporate purposes. Zentalis Pharmaceuticals operates in the biopharmaceutical industry, focusing on developing treatments for inflammatory diseases.

Zentalis Pharmaceuticals reported second quarter 2026 financial results on August 6, 2026. The company held $174.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing a runway into late 2027. Total operating expenses were $44.4 million for the quarter, compared to $36.1 million in the prior year period. Research and development expenses increased to $35.2 million from $27.6 million, driven by a $7.0 million milestone payment to Recurium IP Holdings LLC upon commencement of the Phase 3 ASPENOVA trial. The company announced that enrollment is complete for DENALI Parts 2a and 2b, with Part 2c currently enrolling. Topline data from the registration-intended DENALI Part 2 study is expected in the first half of 2027 to support a potential accelerated approval strategy. Zentalis Pharmaceuticals operates as a clinical oncology innovator developing azenosertib, an investigational WEE1 inhibitor for ovarian cancer.